Unlocking the Therapeutic Potential of Natural Polyphenols in Esophageal Cancer
- PMID: 40120005
- DOI: 10.1007/s11864-025-01308-6
Unlocking the Therapeutic Potential of Natural Polyphenols in Esophageal Cancer
Abstract
Esophageal cancer (EC), one highly malignant upper gastrointestinal cancer, is the eighth most commonly occurring cancer and the sixth leading cause of cancer-related deaths worldwide. Clinically, this malignancy is considered to be one of the most difficult-to-treat cancers, owing to its resistance to common therapies like chemotherapy and radiotherapy, and few targeted therapies are available. There is currently an unmet need for treatment of EC. Polyphenols are naturally occurring plant secondary metabolites in response to environmental threats and injury. Epidemiological evidence suggests that long-term consumption of a polyphenol-rich diet is inversely associated with the risk of cancer. Currently, natural polyphenols have received increased attention for their potential therapeutic effects on EC. In this review, we summarize and discuss recent progress in the therapeutic potential of natural polyphenols in EC, as well as their sources, oral bioavailability, and pharmacokinetics. We review natural polyphenols combined with approved chemotherapy and radiotherapy to overcome challenges faced by either monotherapy. We also discuss the current challenges and future directions to accelerate the clinical application of natural polyphenols in EC. We concluded that natural polyphenols represent promising candidates for the management of EC. Well-designed randomized controlled studies are warranted to verify the efficacy and safety of natural polyphenols for EC. Knowledge gained from this review will outline possible future research directions and should help to develop new therapeutics for this disease.
Keywords: Apoptosis; Bioavailability; Esophageal cancer; Natural polyphenols; Preclinical research.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing Interests: The authors declare no competing interests. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors Ethics Approval: Not applicable.
Similar articles
-
Quercetin as an anticancer agent: Focus on esophageal cancer.J Food Biochem. 2020 Sep;44(9):e13374. doi: 10.1111/jfbc.13374. Epub 2020 Jul 19. J Food Biochem. 2020. PMID: 32686158 Review.
-
Natural polyphenols in cancer therapy.Crit Rev Clin Lab Sci. 2011 Sep-Dec;48(5-6):197-216. doi: 10.3109/10408363.2011.631268. Epub 2011 Dec 5. Crit Rev Clin Lab Sci. 2011. PMID: 22141580 Review.
-
Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective.Int J Nanomedicine. 2017 Apr 4;12:2689-2702. doi: 10.2147/IJN.S131973. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28435252 Free PMC article. Review.
-
Therapeutic potential of plant polyphenols in acute pancreatitis.Inflammopharmacology. 2025 Feb;33(2):785-798. doi: 10.1007/s10787-024-01584-y. Epub 2024 Nov 4. Inflammopharmacology. 2025. PMID: 39497005 Review.
-
The role of artificial intelligence in the development of anticancer therapeutics from natural polyphenols: Current advances and future prospects.Pharmacol Res. 2024 Oct;208:107381. doi: 10.1016/j.phrs.2024.107381. Epub 2024 Aug 30. Pharmacol Res. 2024. PMID: 39218422 Review.
References
References and Recommended Reading
-
- Geng X, Zhao Q, Yuan H, Li HL, Guo CY, Yang T, et al. The important role of whole-process computed tomography guidance for percutaneous gastrostomy in esophageal cancer patients who are unsuitable for or have had unsuccessful attempts with endoscopic and fluoroscopic gastrostomy. BMC Gastroenterol. 2024;24(1):14. - PubMed - PMC - DOI
-
- Mohapatra S, Al Ghamdi SS, Charilaou P, Lopimpisuth C, Das A, Ngamruengphong S. Predictors for lymph node metastasis and survival of patients with T1b esophageal adenocarcinoma treated with surgery and endoscopic therapy: an analysis of the Surveillance, Epidemiology, and End Results database. Gastrointest Endosc. 2024;9:S0016–5107(24)03190–0.
-
- Chandar AK, Keerthy K, Gupta R, Grady WM, Canto MI, Shaheen NJ, et al. Patients With Esophageal Adenocarcinoma With Prior Gastroesophageal Reflux Disease Symptoms Are Similar to Those Without Gastroesophageal Reflux Disease: A Cross-Sectional Study. Am J Gastroenterol. 2024;119(5):823–9. - PubMed - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical